To direct the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to revise certain regulations related to infant and toddler beverages, and for other purposes.

What happened: On April 21, 2026, Representative Sara Jacobs (D-CA51) introduced HR8412 in the House. The bill was immediately referred to the House Committee on Energy and Commerce. It remains in early-stage status with no hearings, markups, or further actions. The bill's text directs the FDA to revise labeling rules for beverages marketed to children 12–36 months old — specifically prohibiting the term 'infant formula' on non-formula products and requiring descriptive names and sugar/sweetener disclosures. No funding, no tax credits, no procurement. The money trail: zero. HR8412 does not authorize or appropriate a single dollar. It is a regulatory directive to an executive agency, not a spending bill. Structural winners and losers: none identified. At this stage, no publicly traded company is materially affected. A regulatory labeling change could eventually impact consumer product companies like Hain Celestial (HAIN) or Danone (OTC: DANOY) if the rule is finalized, but that legislative path has not even begun. No market data provided, no price trends to reference. Timeline: the bill must pass the Energy and Commerce Committee, then the full House, then the Senate, then reconcile differences, then reach the President. As of today, the legislative process has only just started. Absent committee action, this bill has zero probability of near-term enactment.